These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37677989)

  • 1. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
    Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
    Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
    Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
    Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
    Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice.
    Chen X; Chen Y; Liang R; Xiang L; Li J; Zhu Y; He H; Huang L; Zuo D; Li W; Liang X; Dong S; Hu S; Ho M; Feng M
    Mol Cancer Ther; 2022 Jan; 21(1):149-158. PubMed ID: 34725191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
    Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.
    Yu L; Yang X; Huang N; Lang QL; He QL; Jian-Hua W; Liang-Peng G
    Cancer Biol Ther; 2020 Jul; 21(7):597-603. PubMed ID: 32240054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.
    Ofuji K; Saito K; Yoshikawa T; Nakatsura T
    J Hepatocell Carcinoma; 2014; 1():35-42. PubMed ID: 27508174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3 antibodies: a new therapeutic target for liver cancer.
    Feng M; Ho M
    FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
    Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
    Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
    Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
    BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
    Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
    Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.
    Nakamura M; Xu C; Diack C; Ohishi N; Lee RM; Iida S; Kawanishi T; Ohtomo T; Abou-Alfa GK; Chen YC
    Br J Clin Pharmacol; 2018 May; 84(5):944-951. PubMed ID: 29381229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
    Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
    Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
    Wang Y; Liu J; Pan H; Xing J; Wu X; Li Q; Wang Z
    J Vis Exp; 2018 Jul; (137):. PubMed ID: 30059039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application.
    Zhang C; Shi Y; Wu L; Wang C; Liao N; Wang F; Zhao B; Wang Y; Liu X
    ACS Synth Biol; 2022 Feb; 11(2):888-899. PubMed ID: 35113526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.